{"changes":[{"companyHref":"/c/biousawa-com","date":"2026-09-25","documentUrl":null,"domain":"biousawa.com","fact":"latest round","name":"Bio Usawa Inc.","new":{"amountUsd":1705000,"date":"2025-12-17","lead":null,"type":null},"old":{"amountUsd":1705000,"date":"2025-12-17","lead":null,"type":"seed"},"publisher":"sec-edgar","reason":null,"retrievedAt":"2026-05-05","slug":"biousawa-com","status":"attributed","url":"https://whoraisedwhat.com/c/biousawa-com"}],"country":"US","description":"Biosimilars and bio-better manufacturer based in Rwanda producing affordable monoclonal antibody therapies in oncology, ophthalmology and immunology. Serves African patients who currently lack access to anti-VEGF and similar therapies. Targets roughly one-tenth of US pricing through made-in-Africa manufacturing with local R&D talent.","domain":"biousawa.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":37.787936,"lng":-122.40752,"location":"SAN FRANCISCO, CA","name":"Bio Usawa Inc.","rounds":[{"amountQuarantined":false,"amountUsd":1705000,"currency":"USD","date":"2025-12-17","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-05","status":"attributed","url":null},"status":"attributed","type":null,"url":null}],"slug":"biousawa-com","sources":[{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-05","status":"attributed","url":null},{"fact":"existence","publisher":"biousawa.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://biousawa.com"},{"fact":"description","publisher":"biousawa.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://biousawa.com"}],"stage":null,"techStack":["Cloudflare","reCAPTCHA","Google Analytics","Google Tag Manager","Slick 1.8.1","jQuery CDN","jsDelivr","DoubleClick Floodlight","cdnjs","WordPress","PHP","MySQL"],"totalRaisedUsd":1705000,"updatedAt":"2026-05-05"}